South Korea
· Delayed Price · Currency is KRW Mezzion Pharma Co.,Ltd. Statistics
Total Valuation
Mezzion Pharma Co.,Ltd. has a market cap or net worth of KRW 907.09 billion. The enterprise value is 866.70 billion.
| Market Cap | 907.09B |
| Enterprise Value | 866.70B |
Important Dates
The next estimated earnings date is Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Mezzion Pharma Co.,Ltd. has 29.94 million shares outstanding. The number of shares has increased by 10.57% in one year.
| Shares Outstanding | 29.94M |
| Shares Change (YoY) | +10.57% |
| Shares Change (QoQ) | -2.01% |
| Owned by Insiders (%) | 9.42% |
| Owned by Institutions (%) | 5.85% |
| Float | 21.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 44.36 |
| PB Ratio | 16.41 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -97.73 |
| EV / Sales | 42.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -67.79 |
Financial Position
The company has a current ratio of 2.65, with a Debt / Equity ratio of 1.33.
| Current Ratio | 2.65 |
| Quick Ratio | 2.01 |
| Debt / Equity | 1.33 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.06 |
| Interest Coverage | -44.99 |
Financial Efficiency
Return on equity (ROE) is -14.54% and return on invested capital (ROIC) is -15.12%.
| Return on Equity (ROE) | -14.54% |
| Return on Assets (ROA) | -11.45% |
| Return on Capital (ROIC) | -15.12% |
| Revenue Per Employee | 1.19B |
| Profits Per Employee | -521.66M |
| Employee Count | 17 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 2.59 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.34% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -37.34% |
| 50-Day Moving Average | 33,661.00 |
| 200-Day Moving Average | 37,255.00 |
| Relative Strength Index (RSI) | 44.93 |
| Average Volume (20 Days) | 85,952 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Mezzion Pharma Co.,Ltd. had revenue of KRW 20.25 billion and -8.87 billion in losses. Loss per share was -299.41.
| Revenue | 20.25B |
| Gross Profit | 3.22B |
| Operating Income | -15.22B |
| Pretax Income | -8.45B |
| Net Income | -8.87B |
| EBITDA | -13.94B |
| EBIT | -15.22B |
| Loss Per Share | -299.41 |
Balance Sheet
The company has 41.12 billion in cash and 732.03 million in debt, giving a net cash position of 40.39 billion or 1,349.18 per share.
| Cash & Cash Equivalents | 41.12B |
| Total Debt | 732.03M |
| Net Cash | 40.39B |
| Net Cash Per Share | 1,349.18 |
| Equity (Book Value) | 55.07B |
| Book Value Per Share | 1,846.60 |
| Working Capital | 35.42B |
Cash Flow
In the last 12 months, operating cash flow was -12.07 billion and capital expenditures -714.00 million, giving a free cash flow of -12.79 billion.
| Operating Cash Flow | -12.07B |
| Capital Expenditures | -714.00M |
| Free Cash Flow | -12.79B |
| FCF Per Share | -427.07 |
Margins
Gross margin is 15.93%, with operating and profit margins of -75.16% and -43.80%.
| Gross Margin | 15.93% |
| Operating Margin | -75.16% |
| Pretax Margin | -41.75% |
| Profit Margin | -43.80% |
| EBITDA Margin | -68.84% |
| EBIT Margin | -75.16% |
| FCF Margin | -63.15% |
Dividends & Yields
Mezzion Pharma Co.,Ltd. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.57% |
| Shareholder Yield | -10.57% |
| Earnings Yield | -0.99% |
| FCF Yield | -1.41% |
Stock Splits
The last stock split was on April 5, 2022. It was a forward split with a ratio of 3.
| Last Split Date | Apr 5, 2022 |
| Split Type | Forward |
| Split Ratio | 3 |